Previous 10 | Next 10 |
Akero Therapeutics (NASDAQ: AKRO ): Q1 GAAP EPS of -$0.42 beats by $0.19 . More news on: Akero Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SOUTH SAN FRANCISCO, Calif., May 13, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NAS...
In our previous assessment, we compared 13 NASH drug candidates, and our favorite was AK-001 of Akero Therapeutics (AKRO). We emphasized the high likelihood of Akero Therapeutics to reach the best results in NASH treatment among the 2nd wave NASH drug candidates. For those who are interested, ...
SG Blocks (NASDAQ: SGBX ) +100% on Q4 results .. More news on: SG Blocks, Inc., EyeGate Pharmaceuticals, Inc., Kiniksa Pharmaceuticals, Ltd., Stocks on the move, , Read more ...
Akero Therapeutics (NASDAQ: AKRO ) announces positive results from a Phase 2 clinical trial, BALANCED , evaluating lead candidate AKR-001 patients with F1-F4 (minimal fibrosis to severe fibrosis) nonalcoholic steatohepatitis (NASH). More news on: Akero Therapeutics, Inc., Healthcar...
SAN FRANCISCO , March 31, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced that all three AKR-001 dose groups in the BALANCED study met the primary endpoint of absolute change from baseline in liver fat as measured by magnetic resonance imaging – proton ...
SAN FRANCISCO , March 30, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced that the company plans to discuss the primary endpoint and other Week 12 efficacy endpoint results from the ongoing Phase 2a BALANCED study of AKR-001 in patients with biopsy-confir...
Akero Therapeutics (NASDAQ: AKRO ): Q4 GAAP EPS of -$0.55 beats by $0.06 . More news on: Akero Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SAN FRANCISCO , March 16, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) Company developing pioneering medicines designed to restore metabolic balance and improve overall health of NASH patients, to...
In my previous article regarding NASH disease and the potential winners of the first wave drugs, I made a comparison of efficacy of the late stage drug candidates which have better chances to be first in the market of NASH. For those who are interested, please click here . In this article, ...
News, Short Squeeze, Breakout and More Instantly...
Akero Therapeutics Inc. Company Name:
AKRO Stock Symbol:
NASDAQ Market:
Akero Therapeutics Inc. Website:
2024-07-09 15:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 10:00:04 ET Edward Nash from Canaccord Genuity issued a price target of $56.00 for AKRO on 2024-06-12 07:44:00. The adjusted price target was set to $56.00. At the time of the announcement, AKRO was trading at $23.43. The overall price target consensus is at $...
SOUTH SAN FRANCISCO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced initiation of the ...